Silexion Therapeutics Statistics
Total Valuation
SLXN has a market cap or net worth of $1.80 million. The enterprise value is $1.37 million.
Important Dates
The last earnings date was Friday, May 15, 2026, after market close.
| Earnings Date | May 15, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
SLXN has 4.19 million shares outstanding. The number of shares has increased by 4,761.56% in one year.
| Current Share Class | 4.19M |
| Shares Outstanding | 4.19M |
| Shares Change (YoY) | +4,761.56% |
| Shares Change (QoQ) | +2.67% |
| Owned by Insiders (%) | 0.40% |
| Owned by Institutions (%) | 4.18% |
| Float | 4.16M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 5.01 |
| P/TBV Ratio | 6.18 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.00, with a Debt / Equity ratio of 6.84.
| Current Ratio | 1.00 |
| Quick Ratio | 0.59 |
| Debt / Equity | 6.84 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -6,365.50 |
Financial Efficiency
Return on equity (ROE) is -897.46% and return on invested capital (ROIC) is -190.63%.
| Return on Equity (ROE) | -897.46% |
| Return on Assets (ROA) | -123.27% |
| Return on Invested Capital (ROIC) | -190.63% |
| Return on Capital Employed (ROCE) | -2,348.89% |
| Weighted Average Cost of Capital (WACC) | 1.30% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$922,143 |
| Employee Count | 14 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, SLXN has paid $3,000 in taxes.
| Income Tax | 3,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -97.25% in the last 52 weeks. The beta is -0.29, so SLXN's price volatility has been lower than the market average.
| Beta (5Y) | -0.29 |
| 52-Week Price Change | -97.25% |
| 50-Day Moving Average | 0.90 |
| 200-Day Moving Average | 2.71 |
| Relative Strength Index (RSI) | 37.72 |
| Average Volume (20 Days) | 17,321,558 |
Short Selling Information
The latest short interest is 33,126, so 0.79% of the outstanding shares have been sold short.
| Short Interest | 33,126 |
| Short Previous Month | 46,472 |
| Short % of Shares Out | 0.79% |
| Short % of Float | 0.80% |
| Short Ratio (days to cover) | 0.34 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -12.73M |
| Pretax Income | -12.91M |
| Net Income | -12.91M |
| EBITDA | -12.72M |
| EBIT | -12.73M |
| Earnings Per Share (EPS) | -$6.38 |
Full Income StatementBalance Sheet
The company has $2.41 million in cash and $1.99 million in debt, with a net cash position of $424,000 or $0.10 per share.
| Cash & Cash Equivalents | 2.41M |
| Total Debt | 1.99M |
| Net Cash | 424,000 |
| Net Cash Per Share | $0.10 |
| Equity (Book Value) | 291,000 |
| Book Value Per Share | 0.09 |
| Working Capital | 5,000 |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$12.01 million and capital expenditures -$3,000, giving a free cash flow of -$12.02 million.
| Operating Cash Flow | -12.01M |
| Capital Expenditures | -3,000 |
| Depreciation & Amortization | 12,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -12.02M |
| FCF Per Share | -$2.87 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
SLXN does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -4,761.56% |
| Shareholder Yield | -4,761.56% |
| Earnings Yield | -717.72% |
| FCF Yield | -667.96% |
Analyst Forecast
The average price target for SLXN is $6.00, which is 1,297.62% higher than the current price. The consensus rating is "Buy".
| Price Target | $6.00 |
| Price Target Difference | 1,297.62% |
| Analyst Consensus | Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | -10.64% |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on July 29, 2025. It was a reverse split with a ratio of 1:15.
| Last Split Date | Jul 29, 2025 |
| Split Type | Reverse |
| Split Ratio | 1:15 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |
